Profile data is unavailable for this security.
About the company
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. It is engaged in manufacturing, developing, and marketing a range of branded and generic formulations and active pharmaceutical ingredients (APIs). It produces a diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its global specialty portfolio spans advanced products in dermatology, ophthalmology, and onco-dermatology. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its vertically integrated operations deliver medicines to physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents.
- Revenue in INR (TTM)503.08bn
- Net income in INR110.54bn
- Incorporated1993
- Employees43.00k
- LocationSun Pharmaceutical Industries LtdSun House, CTS No. 201 B/1,, Western ExpMUMBAI 400 093IndiaIND
- Phone+91 2 243244324
- Fax+91 2 243244343
- Websitehttps://sunpharma.com/
Mergers & acquisitions
| Acquired company | SUNPHARMA:NSI since announced | Transaction value |
|---|---|---|
| Valstar SA | 18.24% | 31.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | 214.31bn | 26.26bn | 929.73bn | 21.87k | 35.49 | 5.94 | 25.34 | 4.34 | 57.42 | 57.42 | 468.54 | 342.91 | 0.8761 | 1.35 | 4.48 | 9,800,284.00 | 10.84 | 1.43 | 16.64 | 2.22 | 68.60 | 58.52 | 12.37 | 2.04 | 1.22 | 11.88 | 0.1797 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 214.84bn | 42.78bn | 953.51bn | 26.24k | 22.34 | 4.37 | 18.52 | 4.44 | 42.41 | 42.66 | 212.94 | 216.89 | 0.7495 | 1.75 | 5.01 | 8,187,310.00 | 15.00 | 9.05 | 19.96 | 14.01 | 71.43 | 61.15 | 20.01 | 14.33 | 1.58 | 217.94 | 0.0078 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 300.85bn | 53.39bn | 1.01tn | 26.34k | 18.95 | 3.29 | 14.56 | 3.36 | 64.03 | 64.03 | 360.85 | 369.12 | 0.7379 | 1.37 | 3.90 | 11,420,450.00 | 13.31 | 11.37 | 18.14 | 16.02 | 70.69 | 65.86 | 18.03 | 14.63 | 1.36 | 30.69 | 0.1349 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Mankind Pharma Ltd | 110.18bn | 21.15bn | 1.03tn | 19.54k | 48.85 | 9.76 | 40.20 | 9.36 | 52.70 | 52.70 | 274.57 | 263.69 | 0.8786 | 2.02 | 9.46 | 5,638,684.00 | 17.05 | -- | 21.79 | -- | 70.48 | -- | 19.41 | -- | 2.37 | 99.72 | 0.0428 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 112.25bn | 18.02bn | 1.05tn | 14.92k | 58.12 | 13.96 | 40.28 | 9.33 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 265.12bn | 44.75bn | 1.19tn | 27.76k | 26.57 | 4.19 | 21.51 | 4.48 | 55.39 | 55.39 | 328.19 | 351.20 | 0.803 | 1.58 | 5.08 | 9,549,060.00 | 13.58 | 10.09 | 16.44 | 12.40 | 67.01 | 58.63 | 16.92 | 12.66 | 2.82 | 69.41 | 0.016 | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 86.14bn | 18.36bn | 1.57tn | 17.50k | 85.34 | 11.42 | 70.50 | 18.19 | 69.14 | 69.14 | 324.44 | 516.71 | 0.5768 | 1.13 | 4.27 | 4,922,286.00 | 12.29 | 16.55 | 13.32 | 18.22 | 59.91 | 56.24 | 21.31 | 26.38 | 4.80 | -- | 0.0006 | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Sun Pharmaceutical Industries Ltd | 503.08bn | 110.54bn | 4.26tn | 43.00k | 38.54 | 6.17 | 31.15 | 8.48 | 46.12 | 46.12 | 209.89 | 288.06 | 0.6005 | 1.05 | 4.15 | 11,699,470.00 | 13.29 | 7.77 | 16.92 | 10.85 | 79.15 | 71.59 | 22.14 | 14.23 | 2.09 | -- | 0.0358 | 38.64 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 73.70m | 3.07% |
| Life Insurance Corporation of India (Investment Portfolio)as of 13 Sep 2023 | 72.27m | 3.01% |
| SBI Funds Management Ltd.as of 31 Oct 2024 | 51.12m | 2.13% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 39.70m | 1.66% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 25.57m | 1.07% |
| Norges Bank Investment Managementas of 31 Mar 2024 | 25.01m | 1.04% |
| GQG Partners LLCas of 30 Sep 2024 | 23.61m | 0.98% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 2024 | 21.76m | 0.91% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 19.19m | 0.80% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 07 Nov 2024 | 18.31m | 0.76% |
